×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AQST – aquestive therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AQST
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
08:00 am
aqst
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Low
Report
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
11/6
08:07 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/6
06:42 am
aqst
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/6
02:22 am
aqst
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
11/4
08:58 pm
aqst
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
11/4
04:40 pm
aqst
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/4
04:36 pm
aqst
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/4
07:20 am
aqst
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2024
04:36 pm
aqst
aquestive therapeutics, inc.
MISS
Report
-11.9%
aquestive therapeutics, inc.
8/6/2024
04:22 pm
aqst
aquestive therapeutics, inc.
BEAT
Report
-3.9%
aquestive therapeutics, inc.
5/7/2024
04:19 pm
aqst
aquestive therapeutics, inc.
MISS
Report
-6.8%
aquestive therapeutics, inc.
3/5/2024
05:05 pm
aqst
aquestive therapeutics, inc.
MISS
Report
11.3%
aquestive therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
03:47 pm
aqst
Form SC 13G/A Aquestive Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G/A Aquestive Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
11/8
05:32 pm
aqst
Form SC 13G Aquestive Therapeutics, Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G Aquestive Therapeutics, Filed by: BlackRock, Inc.
11/7
04:02 pm
aqst
Form 8-K Aquestive Therapeutics, For: Nov 01
Medium
Report
Form 8-K Aquestive Therapeutics, For: Nov 01
11/6
04:02 pm
aqst
Form 8-K Aquestive Therapeutics, For: Nov 06
Low
Report
Form 8-K Aquestive Therapeutics, For: Nov 06
11/4
04:46 pm
aqst
Form 10-Q Aquestive Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Aquestive Therapeutics, For: Sep 30
11/4
04:41 pm
aqst
Form 8-K Aquestive Therapeutics, For: Nov 04
Low
Report
Form 8-K Aquestive Therapeutics, For: Nov 04
10/25
08:06 am
aqst
Form 8-K Aquestive Therapeutics, For: Oct 25
Low
Report
Form 8-K Aquestive Therapeutics, For: Oct 25
10/24
08:06 am
aqst
Form 8-K Aquestive Therapeutics, For: Oct 24
Low
Report
Form 8-K Aquestive Therapeutics, For: Oct 24
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/5
Form 8-K Aquestive Therapeutics, For: Nov 05
23.6%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
TOP News Decliners
3/11
Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.450 ActVsEst (0.030) - Miss
-40.0%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: